Review



mb49  (CancerTools Org)


Bioz Verified Symbol CancerTools Org is a verified supplier
Bioz Manufacturer Symbol CancerTools Org manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    CancerTools Org mb49
    Mb49, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 99/100, based on 706 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mb49/cancertools+org___153368?v=CancerTools+Org
    Average 99 stars, based on 706 article reviews
    mb49 - by Bioz Stars, 2026-07
    99/100 stars

    Images



    Similar Products

    99
    CancerTools Org mb49
    Mb49, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mb49/cancertools+org___153368?v=CancerTools+Org
    Average 99 stars, based on 1 article reviews
    mb49 - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    86
    Purdue University Cytometry murine bladder cancer cell line mb49
    Combination of T-mfIL12 with immature BMDCs or iPSDCs in the subcutaneous <t>MB49</t> tumor model (A) Combination of T-mfIL12 with immature BMDCs in the subcutaneous MB49 tumor model. A marked inhibition of tumor growth was observed in the T-mfIL12+BMDC group. Significant tumor growth inhibitions compared to the mock group were also seen in the T-01+BMDC and T-mfIL12 monotherapy groups. n = 6 mice per group. Error bars represent standard error of the mean (SEM). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. (B) Combination of T-mfIL12 with immature iPSDCs in the subcutaneous MB49 tumor model. A significant inhibition of tumor growth was observed in the T-mfIL12+iPSDC group, which was comparable to the inhibition seen in the T-mfIL12+BMDC group. n = 6 mice per group. Error bars represent SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
    Murine Bladder Cancer Cell Line Mb49, supplied by Purdue University Cytometry, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mb49/pmc13273829-138-1-19?v=Purdue+University+Cytometry
    Average 86 stars, based on 1 article reviews
    murine bladder cancer cell line mb49 - by Bioz Stars, 2026-07
    86/100 stars
      Buy from Supplier

    Image Search Results


    Combination of T-mfIL12 with immature BMDCs or iPSDCs in the subcutaneous MB49 tumor model (A) Combination of T-mfIL12 with immature BMDCs in the subcutaneous MB49 tumor model. A marked inhibition of tumor growth was observed in the T-mfIL12+BMDC group. Significant tumor growth inhibitions compared to the mock group were also seen in the T-01+BMDC and T-mfIL12 monotherapy groups. n = 6 mice per group. Error bars represent standard error of the mean (SEM). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. (B) Combination of T-mfIL12 with immature iPSDCs in the subcutaneous MB49 tumor model. A significant inhibition of tumor growth was observed in the T-mfIL12+iPSDC group, which was comparable to the inhibition seen in the T-mfIL12+BMDC group. n = 6 mice per group. Error bars represent SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Journal: Molecular Therapy Oncology

    Article Title: Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1

    doi: 10.1016/j.omton.2026.201252

    Figure Lengend Snippet: Combination of T-mfIL12 with immature BMDCs or iPSDCs in the subcutaneous MB49 tumor model (A) Combination of T-mfIL12 with immature BMDCs in the subcutaneous MB49 tumor model. A marked inhibition of tumor growth was observed in the T-mfIL12+BMDC group. Significant tumor growth inhibitions compared to the mock group were also seen in the T-01+BMDC and T-mfIL12 monotherapy groups. n = 6 mice per group. Error bars represent standard error of the mean (SEM). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. (B) Combination of T-mfIL12 with immature iPSDCs in the subcutaneous MB49 tumor model. A significant inhibition of tumor growth was observed in the T-mfIL12+iPSDC group, which was comparable to the inhibition seen in the T-mfIL12+BMDC group. n = 6 mice per group. Error bars represent SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Article Snippet: The murine bladder cancer cell line MB49, originally induced by 7,12-dimethylbenz[a]anthracene, was kindly provided by Dr. Timothy L. Ratliff (Purdue University, USA; RRID: CVCL_7076).

    Techniques: Inhibition

    Immunological assessments of the combination of T-mfIL12 and immature BMDCs (A) Immunohistochemical analysis of representative MB49 tumors from the indicated treatment groups. Increased intratumoral infiltration of CD8 + lymphocytes was most prominent in the T-mfIL12+BMDC group, followed by the T-01+BMDC group. In both groups, elevated levels of CD4 + lymphocyte infiltration were also observed in the same tumor sections. Other groups, except for the mock group, showed moderate levels of CD4 + infiltration. Scale bars: 100 μm. (B) ELISpot assay for IFN-γ expression revealed the highest number of IFN-γ-producing splenocytes in the T-mfIL12+BMDC group, followed by the T-01+BMDC group. Monotherapies with BMDC, T-01, or T-mfIL12, as well as the mock group, did not result in significant increases. n = 3 per group; all samples were analyzed in triplicate. Error bars represent standard deviation (SD). ∗ p < 0.05, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Journal: Molecular Therapy Oncology

    Article Title: Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1

    doi: 10.1016/j.omton.2026.201252

    Figure Lengend Snippet: Immunological assessments of the combination of T-mfIL12 and immature BMDCs (A) Immunohistochemical analysis of representative MB49 tumors from the indicated treatment groups. Increased intratumoral infiltration of CD8 + lymphocytes was most prominent in the T-mfIL12+BMDC group, followed by the T-01+BMDC group. In both groups, elevated levels of CD4 + lymphocyte infiltration were also observed in the same tumor sections. Other groups, except for the mock group, showed moderate levels of CD4 + infiltration. Scale bars: 100 μm. (B) ELISpot assay for IFN-γ expression revealed the highest number of IFN-γ-producing splenocytes in the T-mfIL12+BMDC group, followed by the T-01+BMDC group. Monotherapies with BMDC, T-01, or T-mfIL12, as well as the mock group, did not result in significant increases. n = 3 per group; all samples were analyzed in triplicate. Error bars represent standard deviation (SD). ∗ p < 0.05, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Article Snippet: The murine bladder cancer cell line MB49, originally induced by 7,12-dimethylbenz[a]anthracene, was kindly provided by Dr. Timothy L. Ratliff (Purdue University, USA; RRID: CVCL_7076).

    Techniques: Immunohistochemical staining, Enzyme-linked Immunospot, Expressing, Standard Deviation

    Immunological assessments of the combination of T-mfIL12 and immature iPSDCs (A) Immunohistochemical analysis of representative MB49 tumors from the indicated treatment groups. Increased intratumoral infiltration of CD8 + lymphocytes was observed in both the T-mfIL12+BMDC and T-mfIL12+iPSDC groups. In both groups, CD4 + lymphocyte infiltration was also more prominently observed in the same tumor sections. Other treatment groups, excluding the mock group, exhibited moderate levels of CD4 + T cell infiltration. Scale bars: 100 μm. (B) ELISpot assay showed a high and comparable increase in IFN-γ-producing splenocytes in both the T-mfIL12+BMDC and T-mfIL12+iPSDC groups. n = 3 mice per group; all samples were analyzed in triplicate. Error bars represent standard deviation (SD). ∗∗∗∗ p < 0.0001; NS, not significant.

    Journal: Molecular Therapy Oncology

    Article Title: Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1

    doi: 10.1016/j.omton.2026.201252

    Figure Lengend Snippet: Immunological assessments of the combination of T-mfIL12 and immature iPSDCs (A) Immunohistochemical analysis of representative MB49 tumors from the indicated treatment groups. Increased intratumoral infiltration of CD8 + lymphocytes was observed in both the T-mfIL12+BMDC and T-mfIL12+iPSDC groups. In both groups, CD4 + lymphocyte infiltration was also more prominently observed in the same tumor sections. Other treatment groups, excluding the mock group, exhibited moderate levels of CD4 + T cell infiltration. Scale bars: 100 μm. (B) ELISpot assay showed a high and comparable increase in IFN-γ-producing splenocytes in both the T-mfIL12+BMDC and T-mfIL12+iPSDC groups. n = 3 mice per group; all samples were analyzed in triplicate. Error bars represent standard deviation (SD). ∗∗∗∗ p < 0.0001; NS, not significant.

    Article Snippet: The murine bladder cancer cell line MB49, originally induced by 7,12-dimethylbenz[a]anthracene, was kindly provided by Dr. Timothy L. Ratliff (Purdue University, USA; RRID: CVCL_7076).

    Techniques: Immunohistochemical staining, Enzyme-linked Immunospot, Standard Deviation

    Immunohistochemical analysis of DC surface markers in MB49 tumors Representative tumor sections were stained for CD11c (a marker of DC presence) and CD86 (a marker of DC maturation). Tumors from the BMDC and iPSDC monotherapy groups were CD11c-positive but CD86-negative, indicating the presence of immature DCs. In contrast, tumors from the T-mfIL12+BMDC and T-mfIL12+iPSDC groups were positive for both CD11c and CD86, suggesting the presence of mature DCs. Tumors from the mock and T-mfIL12 monotherapy groups were negative for both markers. These findings suggest that the co-administration of T-mfIL12 may promote DC maturation in the tumor microenvironment. Scale bars: 100 μm.

    Journal: Molecular Therapy Oncology

    Article Title: Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1

    doi: 10.1016/j.omton.2026.201252

    Figure Lengend Snippet: Immunohistochemical analysis of DC surface markers in MB49 tumors Representative tumor sections were stained for CD11c (a marker of DC presence) and CD86 (a marker of DC maturation). Tumors from the BMDC and iPSDC monotherapy groups were CD11c-positive but CD86-negative, indicating the presence of immature DCs. In contrast, tumors from the T-mfIL12+BMDC and T-mfIL12+iPSDC groups were positive for both CD11c and CD86, suggesting the presence of mature DCs. Tumors from the mock and T-mfIL12 monotherapy groups were negative for both markers. These findings suggest that the co-administration of T-mfIL12 may promote DC maturation in the tumor microenvironment. Scale bars: 100 μm.

    Article Snippet: The murine bladder cancer cell line MB49, originally induced by 7,12-dimethylbenz[a]anthracene, was kindly provided by Dr. Timothy L. Ratliff (Purdue University, USA; RRID: CVCL_7076).

    Techniques: Immunohistochemical staining, Staining, Marker